Investors & Media
Board of Directors
Douglas M. Fambrough, III, Ph.D., co-founded Dicerna in 2007 and has served as the Company’s chief executive officer since 2010. Prior to joining Dicerna as CEO, Dr. Fambrough specialized in financing innovative life science technology companies as a general partner with Oxford Bioscience Partners, a Boston-based venture capital firm.
In 2003, Dr. Fambrough and two other investors founded Sirna Therapeutics, a first-generation RNA interference (RNAi) pioneer; he served on Sirna’s Board of Directors until the company was acquired by Merck for $1.1 billion in 2006. Other investments include Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, acquired by Illumina for $600 million; and Cambrios Technologies, which invented and now markets biologically inspired electronic materials for touch screens and flat panel displays. Before joining Oxford, Dr. Fambrough was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute).
Dr. Fambrough graduated from Cornell University and obtained his Ph.D. in genetics at the University of California, Berkeley.
Kevin Buchi, the former president and chief executive officer of Cephalon, Inc. and TetraLogic Pharmaceuticals, joined the Dicerna board of directors in August 2018, and was appointed chairman of the board in January 2019. He previously served as corporate vice president of global branded products at Teva Pharmaceutical Industries Limited from 2011 to May 2012, after Teva acquired Cephalon in October 2011.
Mr. Buchi joined Cephalon in 1991 and, during his tenure, held various leadership positions, including chief financial officer and chief operating officer, before becoming Cephalon’s chief executive officer in December 2010. In addition, Mr. Buchi currently serves as a director of Amneal Pharmaceuticals, Inc. and Benitec Biopharma Ltd. Mr. Buchi has previously served on the boards of several pharmaceutical companies, including EPIRUS Biopharmaceuticals, Inc., Alexza Pharmaceuticals, Inc. and Forward Pharma A/S.
Martin Freed, M.D., has been a member of the Dicerna board of directors since 2016. Dr. Freed has served as an independent consultant to several private pharmaceutical, biotechnology and healthcare companies, specializing in clinical and general pharmaceutical development and clinical and regulatory strategy since February 2015.
Dr. Freed co-founded and served as chief medical officer of Civitas Therapeutics, Inc., from December 2010 to October 2014 (acquired by Acorda Therapeutics, Inc.) and as senior vice president, clinical development of Acorda from October 2014 through January 2015.
In addition, Dr. Freed has served as chief medical officer and has provided strategic and operational planning and execution, as well as medical leadership for clinical pharmacology, development strategy and preclinical development, for multiple pharmaceutical companies including Avila Therapeutics, Inc., Taligen Therapeutics, Adnexus Therapeutics, Inc. (acquired by Bristol-Myers Squibb), and Vitae Pharmaceuticals, Inc.
Dr. Freed spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals, where he served in numerous roles including vice president, clinical development and medical affairs in the metabolism therapeutic area. He has authored over 100 publications or presentations.
Dr. Freed has been Board Certified in Internal Medicine, Nephrology and Clinical Pharmacology. He performed his internal medicine residency at Temple University Hospital and his nephrology fellowship at Yale-New Haven Hospital. A Fellow of the American College of Physicians, Dr. Freed received his B.S. with Distinction in biology from the University of Delaware and his M.D. from Pennsylvania State University’s College of Medicine.
Stephen Hoffman, M.D., Ph.D., the chief executive officer of Aerpio Pharmaceuticals, Inc., has served as a member of the Dicerna board of directors since November 2007. Dr. Hoffman has been a senior advisor to PDL BioPharma, Inc. since February 2014. Prior to that, he served as a managing director at Skyline Ventures, a venture capital firm, from May 2007 until February 2014.
From January 2003 to March 2007, Dr. Hoffman was a general partner at TVM Capital, a venture capital firm. From 1994 to 2002, he served as president, chief executive officer and a member of the board of directors of Allos Therapeutics, Inc., a biopharmaceutical company, where he remained as chairman of the board until it was acquired by Spectrum Pharmaceuticals, Inc. in September 2012. From 1990 to 1994, Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology, both at the University of Colorado. Dr. Hoffman was the scientific founder of Somatogen Inc., a biotechnology company that in 1998 was acquired by Baxter International, Inc., where he held the position of vice president of science and technology from 1987 until 1990.
Dr. Hoffman currently serves on the boards of directors of AcelRx Pharmaceuticals, Inc., Aerpio Pharmaceuticals, Inc., Bicycle Therapeutics Ltd, and Palleon Pharmaceuticals Inc. Previously, he also served on the boards of directors of Genocea Biosciences, Inc., and Sirtris Pharmaceuticals, Inc., a pharmaceutical company that was acquired by GlaxoSmithKline in 2008.
Dr. Hoffman holds a Ph.D. in bio-organic chemistry from Northwestern University and an M.D. from the University of Colorado School of Medicine.
Peter Kolchinsky, Ph.D. is a co-founder and general partner of RA Capital Management, which has been investing in healthcare companies since 2004. He has served as a member of the National Academies Board on Global Science and Technology; authored an e-book titled, “The Entrepreneur’s Guide to a Biotech Startup”; and serves as an advisor to startup companies and non-profits.
Dr. Kolchinsky received his undergraduate degree in biology from Cornell University and a Ph.D. in virology from Harvard University, where he conducted research at Dana-Farber Cancer Institute on the entry mechanism of the human immunodeficiency virus (HIV).
Adam M. Koppel, M.D., Ph.D., managing director of the Bain Capital Life Sciences Fund, has been a member of the Dicerna board of directors since April 2017. He first joined Bain Capital Public Equity in 2003 and was a leader within the firm’s healthcare sector until mid-2014; Dr. Koppel rejoined Bain Capital in 2016.
From mid-2014 to mid-2016, Dr. Koppel was executive vice president of corporate development and chief strategy officer at Biogen. Prior to initially joining Bain Capital, Dr. Koppel was an associate principal at McKinsey & Co. in New Jersey, where he served a variety of healthcare companies. In addition to Dicerna, he serves on the boards of directors of Solid Biosciences, PTC Therapeutics and Trevena.
Dr. Koppel received an M.D. and a Ph.D. in neuroscience from the University of Pennsylvania School of Medicine. He also received an M.B.A. from the Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an A.B. and A.M. in history and science.
Dennis H. Langer, M.D., J.D. has served as a member of the Dicerna board of directors since November 2007. Previously, he was chairman of the board of directors and chief executive officer of AdvanDx, Inc., from January 2013 to August 2014.
Dr. Langer has been a clinical professor in the Department of Psychiatry at Georgetown University School of Medicine since September 2003. From August 2005 to May 2010, he served as managing partner of Phoenix IP Ventures, LLC. From January 2004 to July 2005, he served as president, North America of Dr. Reddy’s Laboratories, Inc. Dr. Langer held several positions at GlaxoSmithKline plc and its predecessor, SmithKline Beecham, from September 1994 through January 2004, culminating with the title of senior vice president of research and development.
Dr. Langer currently serves on the boards of directors of Myriad Genetics, Inc., Pernix Therapeutics Holdings, Inc. and Alzheon, Inc. He previously served on the boards of directors of Auxilium Pharmaceuticals, Inc., Cytogen Corporation, Delcath Systems, Inc., Myrexis, Inc., Pharmacopeia, Inc., and Sirna Therapeutics, Inc.
Dr. Langer received a J.D. from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in biology from Columbia University.
Cynthia Smith has more than 20 years of broad leadership experience within the healthcare industry. Most recently she has served as chief commercial officer and a member of the executive team of ZS Pharma (acquired by AstraZeneca), where she led efforts to transition the company from the development stage to a commercial enterprise.
Prior to joining ZS Pharma, Ms. Smith served as vice president, market access and commercial development at Affymax, Inc. Earlier, she held various senior leadership positions in market access, corporate strategy, government relations and external affairs at Merck & Co. Before beginning her career in the biopharmaceutical industry, Ms. Smith served as a healthcare policy analyst in the White House Office of Management and Budget. She previously served on the board of Nivalis Therapeutics.
Marc Kozin is a professional board member, having served on more than a dozen boards in a variety of roles and on all committees. Previously, Mr. Kozin was a career strategy consultant, having served as president of L.E.K. Consulting’s North American practice from 1997 to 2012.
Mr. Kozin began his career at L.E.K. in 1987 by helping to establish the firm’s Boston office. He has over 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. He also led the development of L.E.K.’s industry-leading life science strategic planning practice.
Mr. Kozin is lead director of UFP Technologies, where he has served as a director since 2006. In January 2013, he joined the strategy advisory board of HealthCare Royalty Partners, where he is vice chairman. On the non-profit side, he serves on the board of The Greenlight Fund.
Since 2012, Mr. Kozin has served on the boards of Endocyte, a small molecule-targeted therapeutic company since sold to Novartis; Dyax, an integrated biotechnology company since sold to Shire; OvaScience, a fertility company since merged with Millendo Therapeutics; and Flex Pharmaceuticals.
Anna Protopapas is president and chief executive officer of Mersana Therapeutics, a clinical-stage antibody drug conjugate company, which she joined in March 2015. Prior to Mersana, Ms. Protopapas was president of Millennium Pharmaceuticals, where she led Takeda Pharmaceutical Co.’s $1.3 billion oncology business.
Ms. Protopapas also served as the executive vice president of global business development for Takeda Pharmaceuticals, where she oversaw global acquisitions, partnering, licensing and venture investing. In this role, she led Takeda’s $12 billion acquisition of Nycomed, a critical step in the company’s globalization. Ms. Protopapas was a member of Takeda’s executive committee and was elected a corporate officer in 2011. Earlier, Ms. Protopapas was an executive officer at Millennium Pharmaceuticals and served in various senior leadership positions, playing an integral role in the company’s transformation from a genomics start-up to a fully integrated oncology leader.
Ms. Protopapas served on the board of directors of Ariad Pharmaceuticals from May 2015 to February 2017, when it was sold to Takeda for $5.2 billion. She also served on the board of Bioverativ from January 2017 to January 2018, when it was sold to Sanofi for $11.6 billion. She earned her bachelor’s degree in science and engineering from Princeton University; a master’s degree in chemical engineering practice from the Massachusetts Institute of Technology; and an M.B.A. from Stanford Graduate School of Business.